Clinical and immunological aspects of post-kala-azar dermal leishmaniasis in Bangladesh

American Journal of Tropical Medicine and Hygiene

Volumn 89, Issue 2, 2013, Pages 345-353

  Islam, Shamim ^a   Kenah, Eben ^b   Bhuiyan, Mohammed Ashraful Alam ^c   Rahman, Kazi Mizanur ^c   Goodhew, Brook ^d   Ghalib, Chowdhury Mohammad ^c   Zahid, M M ^c   Ozaki, Masayo ^e   Rahman, M W ^c   Haque, Rashidul ^c   Luby, Stephen P ^f   Maguire, James H ^g   Martin, Diana ^d   Bern, Caryn ^h  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f STANFORD UNIVERSITY   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; GAMMA INTERFERON; GELATINASE B; INTERLEUKIN 10; MILTEFOSINE; STIBOGLUCONATE SODIUM; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ARTICLE; BANGLADESH; CHILD; CONTROLLED STUDY; DISEASE SURVEILLANCE; FEMALE; HUMAN; HYPOPIGMENTATION; INCIDENCE; INDIAN; MAJOR CLINICAL STUDY; MALE; SCHOOL CHILD; SKIN LEISHMANIASIS; VISCERAL LEISHMANIASIS;

ADOLESCENT; ADULT; AGED; ANTIPROTOZOAL AGENTS; BANGLADESH; CHILD; CHILD, PRESCHOOL; COLLAGENASES; CYTOKINES; FEMALE; HUMANS; INCIDENCE; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; MALE; MATRIX METALLOPROTEINASE INHIBITORS; MIDDLE AGED; RISK FACTORS; YOUNG ADULT;

EID: 84881497533     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.12-0711     Document Type: Article

References (40)

1. Zijlstra EE, Musa AM, Khalil EA, el-Hassan IM, el-Hassan AM, 2003. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis 3: 87-98.
2. Zijlstra EE, el-Hassan AM, 2001. Leishmaniasis in Sudan. Post kala-azar dermal leishmaniasis. Trans R Soc Trop Med Hyg 95 (Suppl 1): S59-S76.
3. Zijlstra EE, el-Hassan AM, Ismael A, 1995. Endemic kala-azar in eastern Sudan: post-kala-azar dermal leishmaniasis. Am J Trop Med Hyg 52: 299-305.
4. Ramesh V, 1995. Post-kala-azar dermal leishmaniasis. Int J Dermatol 34: 85-91.
5. Salotra P, Singh R, 2006. Challenges in the diagnosis of post kalaazar dermal leishmaniasis. Indian J Med Res 123: 295-310.
6. Rahman K, Islam S, Rahman M, Kenah E, Galive C, Zahid M, Maguire J, Rahman M, Haque R, Luby S, Bern C, 2010. Rising incidence of post-kala-azar dermal leishmaniasis in a populationbased study in Bangladesh. Clin Infect Dis 50: 73-76.
7. Ramesh V, 1994. On the differences between post-kala-azar dermal leishmaniasis and leprosy. Trop Doct 24: 120-121.
8. Wolff K, Johnson R, Suurmond R, 2005. Fitzpatrick's Color Atlas & Synopsis of Clinical Dermatology. New York: McGraw-Hill Professional.
9. Cruz I, Canavate C, Rubio JM, Morales MA, Chicharro C, Laguna F, Jimenez-Mejias M, Sirera G, Videla S, Alvar J, 2002. A nested polymerase chain reaction (Ln-PCR) for diagnosing and monitoring Leishmania infantum infection in patients co-infected with human immunodeficiency virus. Trans R Soc Trop Med Hyg 96 (Suppl 1): S185-S189.
10. Aalen O, 1978. Nonparametric inference for a family of counting processes. Ann Stat 6: 701-726.
11. Wegman EJ, Wright IW, 1983. Splines in statistics. J Am Stat Assoc 78: 351-365.
12. Kaplan EL, Meier P, 1958. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481.
13. Peto R, Peto J, 1972. Asymptotically efficient rank invariance test procedures (with discussion). J R Stat Soc Ser A Stat Soc 135: 185-206.
14. Rahman M, Ahmed BN, Faiz MA, Chowdhury MZ, Islam QT, Sayeedur R, Rahman MR, Hossain M, Bangali AM, Ahmad Z, Islam MN, Mascie-Taylor CG, Berman J, Arana B, 2011. Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh. Am J Trop Med Hyg 85: 66-69.
15. Desjeux P, Ramesh V, 2011. Post-kala-azar-dermal leishmaniasis: facing the challenge of eliminating kala-azar from South Asia. Jha TK, Noiri E, eds. Kala Azar in South Asia: Current Status and Challenges Ahead. Heidelberg, Germany: Springer, 111-124.
16. Mondal D, Nasrin KN, Huda MM, Kabir M, Hossain MS, Kroeger A, Thomas T, Haque R, 2010. Enhanced case detection and improved diagnosis of PKDL in a kala-azar-endemic area of Bangladesh. PLoS Negl Trop Dis 4: e832.
17. Uranw S, Ostyn B, Rijal A, Devkota S, Khanal B, Menten J, Boelaert M, Rijal S, 2011. Post-kala-azar dermal leishmaniasis in Nepal: a retrospective cohort study (2000-2010). PLoS Negl Trop Dis 5: e1433.
18. Zijlstra EE, el-Hassan AM, Ismael A, Ghalib HW, 1994. Endemic kala-azar in eastern Sudan: a longitudinal study on the incidence of clinical and subclinical infection and post-kala-azar dermal leishmaniasis. Am J Trop Med Hyg 51: 826-836.
19. Saha S, Mondal S, Ravindran R, Bhowmick S, Modak D, Mallick S, Rahman M, Kar S, Goswami R, Guha SK, Pramanik N, Saha B, Ali N, 2007. IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India. J Immunol 179: 5592-5603.
20. Kumar D, Ramesh V, Verma S, Ramam M, Salotra P, 2009. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine. Ann Trop Med Parasitol 103: 727-730.
21. Pandey K, Das VN, Singh D, Das S, Lal CS, Verma N, Bimal S, Topno RK, Siddiqui NA, Verma RB, Sinha PK, Das P, 2012. Post-kala-azar dermal leishmaniasis in a patient treated with injectable paromomycin for visceral leishmaniasis in India. J Clin Microbiol 50: 1478-1479.
22. Napier LE, Krishnan KV, 1931. A theory of the aetiology and epidemiology of kala-azar in India. Ind Med Gaz 66: 603-609.
23. Rijal S, Chappuis F, Singh R, Bovier PA, Acharya P, Karki BM, Das ML, Desjeux P, Loutan L, Koirala S, 2003. Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. Trans R Soc Trop Med Hyg 97: 350-354.
24. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, Kumar PC, Murray HW, 2000. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 31: 1104-1107.
25. Dorlo TP, Eggelte TA, de Vries PJ, Beijnen JH, 2012. Characterization and identification of suspected counterfeit miltefosine capsules. Analyst (Lond) 137: 1265-1274.
26. Ansari NA, Ramesh V, Salotra P, 2006. Interferon (IFN)-gamma, tumor necrosis factor-alpha, interleukin-6, and IFN-gamma receptor 1 are the major immunological determinants associated with post-kala azar dermal leishmaniasis. J Infect Dis 194: 958-965.
27. Cillari E, Vitale G, Arcoleo F, D'Agostino P, Mocciaro C, Gambino G, Malta R, Stassi G, Giordano C, Milano S, Mansueto S, 1995. In vivo and in vitro cytokine profiles and mononuclear cell subsets in Sicilian patients with active visceral leishmaniasis. Cytokine 7: 740-745.
28. Karp CL, el-Safi SH, Wynn TA, Satti MM, Kordofani AM, Hashim FA, Hag-Ali M, Neva FA, Nutman TB, Sacks DL, 1993. In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferongamma. J Clin Invest 91: 1644-1648.
29. Ismail A, El Hassan AM, Kemp K, Gasim S, Kadaru AE, Moller T, Kharazmi A, Theander TG, 1999. Immunopathology of post kala-azar dermal leishmaniasis (PKDL): T-cell phenotypes and cytokine profile. J Pathol 189: 615-622.
30. Okamoto T, Akuta T, Tamura F, van Der Vliet A, Akaike T, 2004. Molecular mechanism for activation and regulation of matrix metalloproteinases during bacterial infections and respiratory inflammation. Biol Chem 385: 997-1006.
31. Teles RM, Teles RB, Amadeu TP, Moura DF, Mendonca-Lima L, Ferreira H, Santos IM, Nery JA, Sarno EN, Sampaio EP, 2010. High matrix metalloproteinase production correlates with immune activation and leukocyte migration in leprosy reactional lesions. Infect Immun 78: 1012-1021.
32. Quinnell RJ, Courtenay O, 2009. Transmission, reservoir hosts and control of zoonotic visceral leishmaniasis. Parasitology 136: 1915-1934.
33. Napier L, Smith R, Das-Gupta C, Mukerji S, 1933. The infection of Phlebotomus argentipes from dermal leishmanial lesions. Indian J Med Res 21: 173-177.
34. Shortt H, Swaminath CS, 1928. Note on dermal leishmanoid. Indian J Med Res 16: 239-240.
35. Addy M, Nandy A, 1992. Ten years of kala-azar in west Bengal, Part I. Did post-kala-azar dermal leishmaniasis initiate the outbreak in 24-Parganas? Bull World Health Organ 70: 341-346.
36. Bern C, Hightower AW, Chowdhury R, Ali M, Amann J, Wagatsuma Y, Haque R, Kurkjian K, Vaz LE, Begum M, Akter T, Cetre-Sossah CB, Ahluwalia IB, Dotson E, Secor WE, Breiman RF, Maguire JH, 2005. Risk factors for kala-azar in Bangladesh. Emerg Infect Dis 11: 655-662.
37. Malaviya P, Picado A, Singh SP, Hasker E, Singh RP, Boelaert M, Sundar S, 2011. Visceral leishmaniasis in Muzaffarpur district, Bihar, India from 1990 to 2008. PLoS One 6: e14751.
38. Dye C, Wolpert DM, 1988. Earthquakes, influenza and cycles of Indian kala-azar. Trans R Soc Trop Med Hyg 82: 843-850.
39. Jeronimo SM, Teixeira MJ, Sousa A, Thielking P, Pearson RD, Evans TG, 2000. Natural history of Leishmania (Leishmania) chagasi infection in northeastern Brazil: long-term follow-up. Clin Infect Dis 30: 608-609.
40. Sen Gupta PC, 1975. Return of kala-azar. J Indian Med Assoc 65: 89-90.